Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).

Antonio Avallone, Maria Carmela Piccirillo, Gerardo Rosati et al.|Journal of Clinical Oncology|2018

Cited by 1